PMID- 15448035
OWN - NLM
STAT- MEDLINE
DCOM- 20041201
LR  - 20211203
IS  - 1078-0432 (Print)
IS  - 1078-0432 (Linking)
VI  - 10
IP  - 18 Pt 2
DP  - 2004 Sep 15
TI  - Mammalian target of rapamycin inhibition.
PG  - 6382S-7S
AB  - The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that has 
      been increasingly recognized as key to the regulation of cell growth and 
      proliferation. mTOR either directly or indirectly regulates translation 
      initiation, actin organization, tRNA synthesis, ribosome biogenesis, and many 
      other key cell maintenance functions, including protein degradation and 
      transcription functions. Inhibition of mTOR blocks traverse of the cell cycle 
      from the G1 to S phase. Preclinical data show inhibition of tumor growth in a 
      number of cell lines and xenograft models. Clinical trials are ongoing. In 
      metastatic renal cell cancer, both tumor regression and prolonged stabilization 
      have been noted. mTOR inhibition appears to be a key pathway that may be useful 
      in antitumor therapy. Renal cell cancer may be particularly susceptible through 
      both the translation inhibition pathway and pathways that enhance HIF-1alpha gene 
      expression, a factor believed to stimulate growth in metastatic renal cell 
      cancer. Additional clinical trials that use agents that inhibit mTOR are ongoing.
FAU - Dutcher, Janice P
AU  - Dutcher JP
AD  - Comprehensive Cancer Center, Our Lady of Mercy Medical Center, Bronx, New York 
      10466, USA. jpd4401@aol.com
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Clin Cancer Res
JT  - Clinical cancer research : an official journal of the American Association for 
      Cancer Research
JID - 9502500
RN  - 0 (Enzyme Inhibitors)
RN  - EC 2.7.- (Protein Kinases)
RN  - EC 2.7.1.1 (MTOR protein, human)
RN  - EC 2.7.11.1 (TOR Serine-Threonine Kinases)
SB  - IM
MH  - Carcinoma, Renal Cell/*drug therapy
MH  - Clinical Trials, Phase I as Topic
MH  - Clinical Trials, Phase II as Topic
MH  - Enzyme Inhibitors/*therapeutic use
MH  - Humans
MH  - Kidney Neoplasms/*drug therapy
MH  - *Protein Kinases
MH  - TOR Serine-Threonine Kinases
MH  - Treatment Outcome
RF  - 56
EDAT- 2004/09/28 05:00
MHDA- 2004/12/16 09:00
CRDT- 2004/09/28 05:00
PHST- 2004/09/28 05:00 [pubmed]
PHST- 2004/12/16 09:00 [medline]
PHST- 2004/09/28 05:00 [entrez]
AID - 10/18/6382S [pii]
AID - 10.1158/1078-0432.CCR-050008 [doi]
PST - ppublish
SO  - Clin Cancer Res. 2004 Sep 15;10(18 Pt 2):6382S-7S. doi: 
      10.1158/1078-0432.CCR-050008.